Literature DB >> 25263582

Behavioral effects and mechanisms of migraine pathogenesis following estradiol exposure in a multibehavioral model of migraine in rat.

Lydia M M Vermeer1, Eugene Gregory2, Michelle K Winter3, Kenneth E McCarson4, Nancy E J Berman5.   

Abstract

Migraine is one of the most common neurological disorders, leading to more than 1% of total disability reported and over 68 million visits to emergency rooms or physician's offices each year in the United States. Three times as many women as men have migraine, and while the mechanism behind this is not well understood, 17β-estradiol (estradiol) has been implicated to play a role. Studies have demonstrated that exposure to estrogen can lead to activation of inflammatory pathways, changes in sodium gated channel activity, as well as enhanced vasodilation and allodynia. Estradiol receptors are found in trigeminal nociceptors, which are involved in signaling during a migraine attack. The purpose of this study was to investigate the role of estradiol in migraine pathogenesis utilizing a multibehavioral model of migraine in rat. Animals were surgically implanted with a cannula system to induce migraine and behavior was assessed following exposure to a proestrus level of estradiol for total locomotor activity, light and noise sensitivity, evoked grooming patterns, and enhanced acoustic startle response. Results demonstrated decreased locomotor activity, increased light and noise sensitivity, altered facial grooming indicative of allodynia and enhanced acoustic startle. Further examination of tissue samples revealed increased expression of genes associated with inflammation and vasodilation. Overall, this study demonstrates exacerbation of migraine-like behaviors following exposure to estradiol and helps further explain the underlying mechanisms behind sex differences found in this common neurological disorder.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Estrogen; Inflammation; Migraine mechanisms; Vasodilation

Mesh:

Substances:

Year:  2014        PMID: 25263582      PMCID: PMC5822729          DOI: 10.1016/j.expneurol.2014.09.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  58 in total

1.  The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy.

Authors:  M S Smith; M E Freeman; J D Neill
Journal:  Endocrinology       Date:  1975-01       Impact factor: 4.736

2.  Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration.

Authors:  B W Somerville
Journal:  Neurology       Date:  1975-03       Impact factor: 9.910

3.  Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study.

Authors:  Dawn C Buse; Elizabeth W Loder; Jennifer A Gorman; Walter F Stewart; Michael L Reed; Kristina M Fanning; Daniel Serrano; Richard B Lipton
Journal:  Headache       Date:  2013-06-28       Impact factor: 5.887

4.  The faah gene is the first direct target of estrogen in the testis: role of histone demethylase LSD1.

Authors:  Paola Grimaldi; Mariangela Pucci; Sara Di Siena; Daniele Di Giacomo; Valentina Pirazzi; Raffaele Geremia; Mauro Maccarrone
Journal:  Cell Mol Life Sci       Date:  2012-07-17       Impact factor: 9.261

Review 5.  The influence of gender and sex steroids on craniofacial nociception.

Authors:  Brian E Cairns
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

6.  The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test.

Authors:  E M Lichten; J B Lichten; A Whitty; D Pieper
Journal:  Headache       Date:  1996-06       Impact factor: 5.887

Review 7.  Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception.

Authors:  Simon Akerman; Philip R Holland; Jan Hoffmann
Journal:  Cephalalgia       Date:  2013-06       Impact factor: 6.292

Review 8.  Sumatriptan plus naproxen for acute migraine attacks in adults.

Authors:  Simon Law; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2013-10-21

9.  Computer-aided identification of novel protein targets of bisphenol A.

Authors:  Diana Montes-Grajales; Jesus Olivero-Verbel
Journal:  Toxicol Lett       Date:  2013-08-20       Impact factor: 4.372

10.  Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology.

Authors:  Carolyn Bernstein; Rami Burstein
Journal:  J Clin Neurol       Date:  2012-06-29       Impact factor: 3.077

View more
  5 in total

Review 1.  Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP.

Authors:  Diana N Krause; Karin Warfvinge; Kristian Agmund Haanes; Lars Edvinsson
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

2.  Assessing complex movement behaviors in rodent models of neurological disorders.

Authors:  Kenneth E McCarson; Michelle K Winter; Dale R Abrahamson; Nancy E Berman; Peter G Smith
Journal:  Neurobiol Learn Mem       Date:  2018-02-21       Impact factor: 2.877

3.  Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure.

Authors:  Phillip Edward Kunkler; LuJuan Zhang; Philip Lee Johnson; Gerry Stephen Oxford; Joyce Harts Hurley
Journal:  Pain       Date:  2018-03       Impact factor: 7.926

4.  17-β-Estradiol induces spreading depression and pain behavior in alert female rats.

Authors:  Alexander J Sandweiss; Karissa E Cottier; Mary I McIntosh; Gregory Dussor; Thomas P Davis; Todd W Vanderah; Tally M Largent-Milnes
Journal:  Oncotarget       Date:  2017-12-09

5.  Giving Researchers a Headache - Sex and Gender Differences in Migraine.

Authors:  Linda Al-Hassany; Jennifer Haas; Marco Piccininni; Tobias Kurth; Antoinette Maassen Van Den Brink; Jessica L Rohmann
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.